Bausch + Lomb Launches the #LUMIFYEyeDance Challenge on TikTok

Go back to Bausch + Lomb Launches the #LUMIFYEyeDance Challenge on TikTok

Bausch & Lomb Corp. (BLCO) Not Impacted by Xifaxan Loss, Buy Weakness - Cowen

July 28, 2022 12:35 PM EDT

Cowen analyst Ken Cacciatore reiterated an Outperform rating and $35.00 price target on Bausch & Lomb Corp. (NYSE: BLCO) saying the Xifaxan loss doesn't impact the company although it likely traps the 90% ownership of BLCO by Bausch Health Companies Inc. (NYSE:... More

Evercore ISI on Bausch & Lomb Corp. (BLCO) Following Parent's Xifaxan Ruling

July 28, 2022 11:30 AM EDT

Evercore ISI analyst Vijay Kumar reiterated an Outperform rating and $21.00 price target on Bausch & Lomb Corp. (NYSE: BLCO).

The analyst comments "For parent BHC to distribute the remaining ~80% of BLCO shares to holders, there are 2 datapoints that matter. First, there is a... More